Having trouble accessing articles? Reset your cache.

WuXi AppTec prices Hong Kong offering in stormy market

Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) managed to price its Hong Kong listing within its proposed range Friday, potentially raising HK$7.9 billion ($1 billion) based on its proposed number of shares. The listing is the third for a unit of New WuXi Life Science Ltd. since a 2016 deal that took the parent company private.


Read the full 684 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers